Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997304 | 0.94 | ALDH1A1 (0.49) | HPDMEN1KMT2APKMALDH1A1 | |
| SCHEMBL6072903 | 0.90 | HPD (0.47) | HPDMEN1KMT2APKMALDH1A1 | |
| SCHEMBL997302 | 0.90 | ALDH1A1 (0.59) | HPDMEN1KMT2APKMALDH1A1 | |
| SCHEMBL8893024 | 0.84 | HPD (0.46) | HPDMEN1KMT2APKMALDH1A1 | |
| SCHEMBL12466651 | 0.83 | MAPT (0.53) | MEN1KMT2APKMALDH1A1MAPT | |
| SCHEMBL31191230 | 0.82 | ALDH1A1 (0.45) | MEN1KMT2APKMALDH1A1MAPT | |
| SCHEMBL8443380 | 0.81 | MAPT (0.54) | MEN1KMT2APKMALDH1A1MAPT | |
| SCHEMBL6487852 | 0.81 | ALDH1A1 (0.55) | HPDMEN1KMT2APKMALDH1A1 | |
| SCHEMBL6487862 | 0.81 | ALDH1A1 (0.55) | HPDMEN1KMT2APKMALDH1A1 | |
| SCHEMBL15498664 | 0.80 | ALDH1A1 (0.50) | KMT2APKMALDH1A1MAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247790-B1 | STING ANTAGONISTS AND USES THEREOF | REGOR PHARMACEUTICALS INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240002368-A1 | STING ANTAGONISTS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-3222606-B1 | CARBOXYLIC ACID PREPARATION METHOD | ZHEJIANG ZHUJI UNITED CHEMICALS CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| US-10167246-B2 | Preparative method for carboxylic acids | ZHEJIANG ZHUJI UNITED CHEMICALS CO., LTD (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20170369412-A1 | Preparative method for carboxylic acids | ZHEJIANG ZHUJI UNITED CHEMICALS CO., LTD | 2017-12-28 | — | — | US | disclosed |
| EP-3222606-A1 | CARBOXYLIC ACID PREPARATION METHOD | Zhejiang Zhuji United Chemicals Co., Ltd (CN) | 2017-09-27 | — | — | EP | disclosed |
| WO-2006032987-A1 | INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF ARTERIOSCLEROSIS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369412-A1 | Preparative method for carboxylic acids | CBR3, CBR1, QPCT | HPD 82/4885MEN1 4673/4885KMT2A 2467/4885 |
| US-20240002368-A1 | STING ANTAGONISTS AND USES THEREOF | STING1, TBK1, CGAS | HPD 4508/4885MEN1 1364/4885KMT2A 4045/4885 |
| US-10167246-B2 | Preparative method for carboxylic acids | CBR3, CBR1, QPCT | HPD 82/4885MEN1 4673/4885KMT2A 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.